China Regenerative Medicine International Limited (8158) AI Stock Analysis

China Regenerative Medicine International Limited

(HKEX:8158)

Select Model

Rating:66Neutral

Price Target:HKD 0.24▼(-2.86% Downside)

Action:reiterated

Date:09/18/26

The score is led by improving financial performance (strong TTM growth, solid margins, improved leverage, and better free cash flow) and a very low P/E that supports valuation. These positives are tempered by mixed technicals (short-term strength but weaker longer-term trend and stretched momentum indicators) and the company’s history of volatile results and cash-flow consistency risks.

Positive Factors

Revenue and ProfitabilityStrong TTM revenue growth combined with healthy gross and net margins indicates meaningful commercial traction and current earnings capacity. If maintained, this combination can strengthen internal funding, support continued investment in healthcare activities, and improve resilience over the next several quarters.

Negative Factors

Revenue VolatilityLarge year-to-year revenue swings make the current growth rate harder to treat as a stable trend. Volatile demand or business performance can reduce forecasting confidence, complicate resource planning, and make future margins and earnings less dependable even when the latest TTM results are strong.

China Regenerative Medicine International Limited (8158) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 74.54M
Dividend Yield: ―
Average Volume (3M): 61.12K
Price to Earnings (P/E): 2.5
Beta (1Y): -0.35
Revenue Growth: 48.39%
EPS Growth: 397.25%
Country: Hong Kong
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

China Regenerative Medicine International Limited Business Overview & Revenue Model

Company Description

China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health mana...

China Regenerative Medicine International Limited Financial Statement Overview

Summary

TTM shows strong revenue growth (+35.39%), healthy profitability (gross margin ~56%, net margin ~28%), improved leverage (debt-to-equity down to ~0.67x), and much stronger free cash flow (~15.6M). Offsetting factors are high historical volatility (including a major 2023 loss), inconsistent operating cash flow in prior years, and a note of negative EBIT in 2025 despite profitability, which raises sustainability/earnings-quality risk.

Income Statement

71Positive

Balance Sheet

57Neutral

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	107.27M	72.06M	90.62M	69.49M	41.54M	282.90M
Gross Profit	60.51M	41.92M	57.65M	19.42M	37.62M	67.73M
EBITDA	24.92M	8.26M	29.84M	-95.40M	9.92M	65.11M
Net Income	29.85M	27.52M	17.75M	-107.70M	4.55M	51.83M
Balance Sheet
Total Assets	143.24M	168.06M	135.71M	185.90M	275.91M	259.14M
Cash, Cash Equivalents and Short-Term Investments	1.82M	8.17M	57.45M	3.33M	1.85M	9.93M
Total Debt	38.25M	51.31M	53.69M	50.19M	72.01M	35.82M
Total Liabilities	86.48M	114.58M	110.51M	174.10M	172.00M	147.41M
Stockholders Equity	56.76M	53.47M	25.20M	11.79M	103.92M	111.73M
Cash Flow
Free Cash Flow	15.55M	4.03M	17.68M	6.06M	-20.25M	-3.83M
Operating Cash Flow	15.62M	4.10M	18.30M	6.34M	-17.65M	-3.02M
Investing Cash Flow	-70.00K	-70.00K	-622.00K	-262.00K	-2.59M	9.27M
Financing Cash Flow	-16.90M	-19.11M	2.37M	-7.36M	7.32M	-1.39M

China Regenerative Medicine International Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price0.24

Price Trends

50DMA0.24Negative

100DMA0.25Negative

200DMA0.31Negative

Market Momentum

MACD-0.00Positive

RSI44.17Neutral

STOCH51.52Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8158, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.24, and below the 200-day MA of 0.31, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 51.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8158.

China Regenerative Medicine International Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:8158 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:6998	70Outperform	HKD 3.26B	4.47	10.99%	―	1417.68%	660.14%
HK:8158	66Neutral	HKD 74.54M	2.49	54.16%	―	48.39%	397.25%
HK:2181	57Neutral	HKD 1.79B	17.76	48.25%	―	88.38%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:2126	49Neutral	HKD 925.48M	-2.35	-66.16%	―	67.48%	43.84%
HK:2171	45Neutral	HKD 6.32B	-56.08	-9.45%	―	68.12%	81.84%
HK:2898	42Neutral	HKD 970.43M	-8.74	-39.21%	―	―	―

* Healthcare Sector Average

Performance Comparison

HK:8158 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:8158	China Regenerative Medicine International Limited	0.24	-0.34	-58.47%
HK:6998	Genor Biopharma Holdings Limited	1.62	-1.51	-48.24%
HK:2126	JW (Cayman) Therapeutics Co. Ltd.	2.22	-1.82	-45.05%
HK:2171	CARsgen Therapeutics Holdings Ltd.	10.63	-6.92	-39.43%
HK:2181	Mabpharm Limited	0.43	-0.09	-16.35%
HK:2898	Sunho Biologics,Inc.	6.39	-1.61	-20.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026

China Regenerative Medicine International Limited AI Stock Analysis